Cooper Financial Group Buys 240 Shares of Cencora, Inc. (NYSE:COR)

Cooper Financial Group increased its stake in shares of Cencora, Inc. (NYSE:COR) by 8.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,211 shares of the company’s stock after acquiring an additional 240 shares during the quarter. Cooper Financial Group’s holdings in Cencora were worth $721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of COR. Concord Wealth Partners purchased a new position in shares of Cencora in the third quarter worth $30,000. SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora in the second quarter valued at about $36,000. Ashton Thomas Securities LLC bought a new position in shares of Cencora during the third quarter valued at about $41,000. Fairscale Capital LLC purchased a new stake in shares of Cencora during the second quarter worth about $54,000. Finally, Modus Advisors LLC bought a new stake in shares of Cencora in the fourth quarter worth about $54,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

Shares of COR opened at $236.10 on Tuesday. The business has a 50-day simple moving average of $237.82 and a two-hundred day simple moving average of $233.54. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 52 week low of $214.77 and a 52 week high of $253.27. The stock has a market cap of $45.63 billion, a price-to-earnings ratio of 31.44, a PEG ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Wall Street Analyst Weigh In

COR has been the subject of a number of recent analyst reports. Barclays raised their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Bank of America reiterated a “neutral” rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Leerink Partners dropped their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 over the last 90 days. 15.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.